KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Non-Current Assets (2019 - 2022)

Historic Other Non-Current Assets for Esperion Therapeutics (ESPR) over the last 4 years, with Q3 2022 value amounting to $50.0 million.

  • Esperion Therapeutics' Other Non-Current Assets changed 0.0% to $50.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was $50.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $50.0 million for FY2021, which is N/A changed from last year.
  • Latest data reveals that Esperion Therapeutics reported Other Non-Current Assets of $50.0 million as of Q3 2022, which was down 0.0% from $50.0 million recorded in Q2 2022.
  • In the past 5 years, Esperion Therapeutics' Other Non-Current Assets ranged from a high of $50.0 million in Q3 2021 and a low of $928000.0 during Q2 2019
  • In the last 4 years, Esperion Therapeutics' Other Non-Current Assets had a median value of $1.3 million in 2020 and averaged $23.3 million.
  • Examining YoY changes over the last 5 years, Esperion Therapeutics' Other Non-Current Assets showed a top increase of 3943.97% in 2020 and a maximum decrease of 2221.29% in 2020.
  • Esperion Therapeutics' Other Non-Current Assets (Quarter) stood at $928000.0 in 2019, then soared by 39.44% to $1.3 million in 2020, then soared by 3763.99% to $50.0 million in 2021, then changed by 0.0% to $50.0 million in 2022.
  • Its Other Non-Current Assets stands at $50.0 million for Q3 2022, versus $50.0 million for Q2 2022 and $50.0 million for Q1 2022.